EHA 2021 | Real-world data on axi-cel for patients with large B-cell lymphoma
David Miklos, BSc, MD, PhD, Stanford University, Stanford, CA, discusses the outcomes of patients with large B-cell lymphoma who receive the chimeric antigen receptor T-cell (CAR-T) therapy axicabtagene ciloleucel. Prof. Miklos gives an overview of the approval of axi-cel, based on data from the ZUMA-2 trial (NCT02601313), and highlights findings from a recent analysis of real-world data from 275 lymphoma patients who received axi-cel. Prof. Miklos reports that real-world data analysis validated results seen in clinical trials, with a complete response rate of 60%. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
David Miklos, BSc, MD, PhD, has participated in scientific or clinical advisory boards with Adaptive Biotechnologies, Novartis, Juno-Celgene-BMS, Kite-Gilead, Pharmacyclics-Abbvie, Janssen, AlloGene, Precision Bioscience, Miltenyi Biotech, Adicet and Takeda; and has performed industry contracted research for Pharmacyclics-Abbvie, Kite-Gilead, Novartis Allogene, Roche, Genentech, Becton Dickinson, Isoplexis, Miltenyi and Adaptive Biotechnologies.
